Agentic AI for Large Pharma
Scale execution capacity across global portfolios — without scaling biometrics headcount.
Large pharma managing 100–500+ trials face a core constraint: execution capacity does not scale with portfolio complexity.
Biometrics and data workflows drive cost, while 6–8 month database lock delays defer $3–5M per study.
Maxis AI introduces a supervised execution layer — enabling scalable, AI-driven clinical operations while strengthening governance across global clinical programs.
Human-in-the-loop validation · Audit traceability
Each offering maps directly to an execution constraint limiting portfolio throughput.
Portfolio Data Quality and RBQM Oversight
- Unified visibility across trials and CRO partners
- Continuous detection of data quality risks
AI-Driven Clinical Data Management
- Automated data cleaning and validation
- Faster database readiness and submission timelines
AI-Supported Statistical Programming
- Automated dataset preparation and validation
- Improved biometrics efficiency and scalability
Operational Oversight and Governance
- Continuous monitoring across clinical workflows
- Stronger governance visibility across global programs
Where Large Pharma Clinical Execution Often Slows
Execution scalability typically constrains biometrics and readiness layers.
Portfolio data quality remains fragmented
Manual review slows database readiness
CRO execution varies across programs
Biometrics throughput becomes a bottleneck
Protocol and SAP changes delay submissions
AI governance slows enterprise adoption
What Improves with AI-Led Clinical Execution
With Agentic AI for large pharma, execution becomes structured and globally coordinated.
Unified data quality execution across studies
Faster database readiness with supervised resolution
More consistent CRO and vendor oversight
Improved biometrics throughput and readiness
Better control over protocol and SAP changes
Pilot-safe AI adoption with governance built in
Recommended Approach
Deploy supervised AI execution across biometrics and data management workflows first — the highest-leverage layers for large pharma. Sponsors that do this accelerate database lock by 40–50%, recover $3–5M per trial, and establish unified portfolio-level oversight across CRO partners.
Unified Governance. $3–5M Recovered. Per Trial. Submission Accelerated.
Database lock delays were deferring $3–5M per study. See how a large pharma improved execution control across 200+ global trials.
200+
Trials unified in one view
40–50%
Faster DB lock
$3–5M
Value recovered per trial
8–12 Wks
Submission prep (from 3–4 mo)
All You Need to Know
It embeds supervised execution across biometrics and clinical workflows, improving readiness visibility and throughput consistency.
It allows execution capacity to scale independently of biometrics staffing while maintaining governance controls.
Through unified portfolio oversight, traceable workflows, and structured supervision thresholds.
Biometrics efficiency, governance visibility, and database readiness timelines.
By coordinating structured workflows under governance controls, improving execution predictability across regions and partners.
Explore the Agentic AI Platform.
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.